- Home
- ATAI vs PRTA Comparison
ATAI vs PRTA Comparison
Compare ATAI & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- PRTA
- Stock Information
- Founded
- ATAI 2018
- PRTA 2012
- Country
- ATAI Germany
- PRTA Ireland
- Employees
- ATAI N/A
- PRTA N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- ATAI Health Care
- PRTA Health Care
- Exchange
- ATAI Nasdaq
- PRTA Nasdaq
- Market Cap
- ATAI 444.7M
- PRTA 472.1M
- IPO Year
- ATAI 2021
- PRTA N/A
- Fundamental
- Price
- ATAI $4.66
- PRTA $8.37
- Analyst Decision
- ATAI Strong Buy
- PRTA Buy
- Analyst Count
- ATAI 3
- PRTA 10
- Target Price
- ATAI $13.33
- PRTA $12.29
- AVG Volume (30 Days)
- ATAI 5.2M
- PRTA 937.9K
- Earning Date
- ATAI 08-14-2025
- PRTA 11-11-2025
- Dividend Yield
- ATAI N/A
- PRTA N/A
- EPS Growth
- ATAI N/A
- PRTA N/A
- EPS
- ATAI N/A
- PRTA N/A
- Revenue
- ATAI $2,309,000.00
- PRTA $10,341,000.00
- Revenue This Year
- ATAI $661.36
- PRTA N/A
- Revenue Next Year
- ATAI N/A
- PRTA $389.77
- P/E Ratio
- ATAI N/A
- PRTA N/A
- Revenue Growth
- ATAI 510.85
- PRTA N/A
- 52 Week Low
- ATAI $1.03
- PRTA $4.32
- 52 Week High
- ATAI $5.34
- PRTA $22.71
- Technical
- Relative Strength Index (RSI)
- ATAI 58.92
- PRTA 57.08
- Support Level
- ATAI $4.50
- PRTA $8.19
- Resistance Level
- ATAI $4.99
- PRTA $8.50
- Average True Range (ATR)
- ATAI 0.35
- PRTA 0.34
- MACD
- ATAI -0.04
- PRTA -0.07
- Stochastic Oscillator
- ATAI 35.87
- PRTA 41.95
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.